Skip to main content
BrainCited

Acetyl-L-Carnitine Age-Related Cognitive Decline

C エビデンス 小規模研究からのエビデンスは限られていますが、いくつかの肯定的なシグナルがあります。

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dacetyl\u002Dl\u002Dcarnitine\u0026condition\u003Dcognitive\u002Ddecline'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

結論

Mixed results in healthy adults but more consistently positive outcomes in elderly populations with existing cognitive concerns. Used as a prescription drug in some European countries for cognitive impairment.

Key Study Findings

Randomized Controlled Trial
Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized …
Dose: None vs: None Outcome: Cognitive decline 効果: None None

対象集団: Alzheimer's disease patients

Systematic Review
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update.
Dose: None vs: None Outcome: None 効果: None None

対象集団: None

Review
Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies.
Dose: None vs: None Outcome: None 効果: None None

対象集団: Chronic pain patients (preclinical review)

Review
Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy …
Dose: None vs: None Outcome: None 効果: None None

対象集団: Parkinson's disease patients

Controlled Clinical Trial
Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine.
Dose: mitochondrial cofactors + antioxidants vs: control diet Outcome: cognitive function in aged dogs 効果: improved learning and memory None

対象集団: Aged beagle dogs

Randomized Controlled Trial n=106 Double-blind
A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in …
Dose: None vs: placebo Outcome: None 効果: None p = 0.0083

対象集団: Alzheimer's disease patients

Key Statistics

14

研究数

1000

参加者数

Positive

C

グレード

Referenced Papers

The Cochrane database … 2015 33 件の引用
The Cochrane database … 2003 94 件の引用
La Clinica terapeutica 1990 3 件の引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

general:
500-2,000 mg/day
cognitivesupport:
1,500-3,000 mg/day

上限量: Well-tolerated up to 3,000 mg/day

研究で検討された用量

用量 期間 効果 N
None -- Positive --
None -- Positive --
None -- Mixed --
None -- Mixed --
mitochondrial cofactors + antioxidants -- Positive --
None -- Positive 106
None -- Positive 427
None 8.0 weeks Positive --

推奨摂取タイミング: Morning, on empty stomach or with meals

Safety & Side Effects

報告されている副作用

  • Gastrointestinal discomfort (nausea, vomiting, diarrhea)
  • Fishy body odor
  • Restlessness or insomnia
  • Increased appetite

既知の相互作用

  • Anticoagulants (may increase bleeding risk)
  • Thyroid medications (may enhance thyroid hormone effects)
  • AZT (antiretroviral — may reduce neuropathy)

耐容上限摂取量: Well-tolerated up to 3,000 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does Acetyl-L-Carnitine help with Age-Related Cognitive Decline?
Based on 14 studies with 1,000 participants, there is limited but promising evidence that Acetyl-L-Carnitine may support Age-Related Cognitive Decline management. Our evidence grade is C (Some Evidence).
How much Acetyl-L-Carnitine should I take for Age-Related Cognitive Decline?
Studies have used various dosages. A commonly studied range is 500-2,000 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Acetyl-L-Carnitine?
Reported side effects may include Gastrointestinal discomfort (nausea, vomiting, diarrhea), Fishy body odor, Restlessness or insomnia, Increased appetite. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Acetyl-L-Carnitine and Age-Related Cognitive Decline?
We rate the evidence as Grade C (Some Evidence). This rating is based on 14 peer-reviewed studies with 1,000 total participants. The overall direction of effect is positive.

References

  1. [1] Wankiun Lee et al.. Medicine (Baltimore). 2024. Comparative study of choline alfoscerate as a combination therapy with donepezil: A mixed double-blind randomized controlled and open-label observation trial. doi:10.1097/MD.0000000000038067 PubMed
  2. [2] Manuela Pennisi et al.. Nutrients. 2020. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. doi:10.3390/nu12051389 PubMed
  3. [3] Oliver T Phillipson. Ageing Res Rev. 2017. Alpha-synuclein, epigenetics, mitochondria, metabolism, calcium traffic, & circadian dysfunction in Parkinson's disease. An integrated strategy for management. doi:10.1016/j.arr.2017.09.006 PubMed
  4. [4] Mariagrazia Grilli. J Pain Res. 2017. Chronic pain and adult hippocampal neurogenesis: translational implications from preclinical studies. doi:10.2147/JPR.S146399 PubMed
  5. [5] Shikha Snigdha et al.. Neurobiol Aging. 2016. Effect of mitochondrial cofactors and antioxidants supplementation on cognition in the aged canine. doi:10.1016/j.neurobiolaging.2015.09.015 PubMed
  6. [6] Ruth Remington et al.. J Alzheimers Dis. 2015. A Phase II Randomized Clinical Trial of a Nutritional Formulation for Cognition and Mood in Alzheimer's Disease. doi:10.3233/JAD-142499 PubMed
  7. [7] Nuala Livingstone et al.. Cochrane Database Syst Rev. 2015. Pharmacological interventions for cognitive decline in people with Down syndrome. doi:10.1002/14651858.CD011546.pub2 PubMed
  8. [8] Debora Cutuli et al.. Front Aging Neurosci. 2014. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. doi:10.3389/fnagi.2014.00220 PubMed
  9. [9] A Chan et al.. J Nutr Health Aging. 2010. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. doi:10.1007/s12603-010-0054-5 PubMed
  10. [10] James Suchy et al.. Nutr Res. 2009. Dietary supplementation with a combination of alpha-lipoic acid, acetyl-L-carnitine, glycerophosphocoline, docosahexaenoic acid, and phosphatidylserine reduces oxidative damage to murine brain … doi:10.1016/j.nutres.2008.11.004 PubMed
  11. [11] Parris M Kidd. Altern Med Rev. 2008. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. PubMed
  12. [12] N W Milgram et al.. FASEB J. 2007. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. doi:10.1096/fj.07-8531com PubMed
  13. [13] S Hudson et al.. Cochrane Database Syst Rev. 2003. Acetyl-L-carnitine for dementia. doi:10.1002/14651858.CD003158 PubMed
  14. [14] P M Kidd. Altern Med Rev. 1999. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. PubMed
  15. [15] M Neri et al.. Clin Ter. 1990. [Methodology of a clinical controlled study of L-acetylcarnitine]. PubMed
  16. [16] W M Herrmann et al.. Int J Clin Pharmacol Res. 1990. Pharmaco-electroencephalographic and clinical effects of the cholinergic substance--acetyl-L-carnitine--in patients with organic brain syndrome. PubMed

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。